Eli Lilly and Company
CD73 INHIBITORS
Last updated:
Abstract:
The present invention provides 5-[5]-[2-cycloalkyl]-6-pyridazin-3-yl]-1H-pyrimidine-2,4-dione compounds, or pharmaceutically acceptable salts thereof, that inhibit the activity of CD73 and are useful in treating cancer.
Status:
Application
Type:
Utility
Filling date:
22 Feb 2019
Issue date:
7 Jan 2021